» Articles » PMID: 36142877

Correlation Between Type I Interferon Associated Factors and COVID-19 Severity

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Sep 23
PMID 36142877
Authors
Affiliations
Soon will be listed here.
Abstract

Antiviral type I interferons (IFN) produced in the early phase of viral infections effectively inhibit viral replication, prevent virus-mediated tissue damages and promote innate and adaptive immune responses that are all essential to the successful elimination of viruses. As professional type I IFN producing cells, plasmacytoid dendritic cells (pDC) have the ability to rapidly produce waste amounts of type I IFNs. Therefore, their low frequency, dysfunction or decreased capacity to produce type I IFNs might increase the risk of severe viral infections. In accordance with that, declined pDC numbers and delayed or inadequate type I IFN responses could be observed in patients with severe coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as compared to individuals with mild or no symptoms. Thus, besides chronic diseases, all those conditions, which negatively affect the antiviral IFN responses lengthen the list of risk factors for severe COVID-19. In the current review, we would like to briefly discuss the role and dysregulation of pDC/type I IFN axis in COVID-19, and introduce those type I IFN-dependent factors, which account for an increased risk of COVID-19 severity and thus are responsible for the different magnitude of individual immune responses to SARS-CoV-2.

Citing Articles

The role of inflammatory gene polymorphisms in severe COVID-19: a review.

Yip J, Oo A, Ng Y, Chin K, Tan K, Chu J Virol J. 2024; 21(1):327.

PMID: 39707400 PMC: 11662554. DOI: 10.1186/s12985-024-02597-3.


New-onset Systemic Lupus Erythematosus Manifestation Following COVID-19: A Case Report and Literature Review.

Sumichika Y, Temmoku J, Saito K, Yoshida S, Matsumoto H, Watanabe G Intern Med. 2024; 63(10):1491-1498.

PMID: 38369349 PMC: 11157318. DOI: 10.2169/internalmedicine.3211-23.


Overview of anti-viral effects of probiotics via immune cells in pre-, mid- and post-SARS-CoV2 era.

Kanauchi O, Low Z, Jounai K, Tsuji R, AbuBakar S Front Immunol. 2023; 14:1280680.

PMID: 38116008 PMC: 10728489. DOI: 10.3389/fimmu.2023.1280680.


Differential Type-I Interferon Response in Buffy Coat Transcriptome of Individuals Infected with SARS-CoV-2 Gamma and Delta Variants.

da Fonseca G, Cavalcante L, Brustolini O, Luz P, Pires D, Jalil E Int J Mol Sci. 2023; 24(17).

PMID: 37685953 PMC: 10487928. DOI: 10.3390/ijms241713146.


Renin-Angiotensin System and Sex Differences in COVID-19: A Critical Assessment.

Chappell M Circ Res. 2023; 132(10):1320-1337.

PMID: 37167353 PMC: 10171311. DOI: 10.1161/CIRCRESAHA.123.321883.


References
1.
Llor C, Ouchi D, Giner-Soriano M, Garcia-Sangenis A, Bjerrum L, Morros R . Correlation between Previous Antibiotic Exposure and COVID-19 Severity. A Population-Based Cohort Study. Antibiotics (Basel). 2021; 10(11). PMC: 8615228. DOI: 10.3390/antibiotics10111364. View

2.
Kompaniyets L, Goodman A, Belay B, Freedman D, Sucosky M, Lange S . Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death - United States, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021; 70(10):355-361. PMC: 7951819. DOI: 10.15585/mmwr.mm7010e4. View

3.
Elhabyan A, Elyaacoub S, Sanad E, Abukhadra A, Elhabyan A, Dinu V . The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review. Virus Res. 2020; 289:198163. PMC: 7480444. DOI: 10.1016/j.virusres.2020.198163. View

4.
Peruzzi B, Bencini S, Capone M, Mazzoni A, Maggi L, Salvati L . Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. Immunology. 2020; 161(4):345-353. PMC: 7692244. DOI: 10.1111/imm.13254. View

5.
Rajput S, Paliwal D, Naithani M, Kothari A, Meena K, Rana S . COVID-19 and Gut Microbiota: A Potential Connection. Indian J Clin Biochem. 2021; 36(3):266-277. PMC: 7818076. DOI: 10.1007/s12291-020-00948-9. View